← 홈

Antibody

1,830개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-11 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,830개
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab Combined With Chemotherapy)

Gut Microbiota; NSCLC · Gut Microbiota

#GutMicrobiota#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleMerckPhase 1

pembrolizumab (Keytruda, Pembrolizumab Extended)

Metastatic Cancer · Metastatic Cancer

#MetastaticCancer#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab Immunotherapy)

Non-Small Cell Lung Cancer; Non-squamous Non-small-cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleMerckPhase 3

pembrolizumab (Keytruda, Pembrolizumab Monotherapy)

Recurrent Head and Neck Cancer; Metastatic Head and Neck Cancer · Recurrent Head and Neck Cancer

#RecurrentHeadandNeckCancer#Antibody#Phase3#항체#면역항체+3
효능 ORR 16%임상시험 1상태 RECRUITING
AntibodystaleMerckPhase 1

pembrolizumab (Keytruda, Pembrolizumab Standard)

Metastatic Cancer · Metastatic Cancer

#MetastaticCancer#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleMerckPhase 3

pembrolizumab (Keytruda, Pembrolizumab after randomization)

Metastatic NSCLC · Metastatic NSCLC

#MetastaticNSCLC#Antibody#Phase3#항체#면역항체+2
효능 ORR 31.9%임상시험 1상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab alone)

Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleMerckPhase 3

pembrolizumab (Keytruda, Pembrolizumab and Chemotherapy drugs)

Non-small-cell Lung Cancer · Non-small-cell Lung Cancer

#Non-small-cellLungCancer#Antibody#Phase3#항체#면역항체+2
효능 ORR 62.1%임상시험 1상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel)

Metastatic Urothelial Carcinoma · Metastatic Urothelial Carcinoma

#MetastaticUrothelialCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleMerckPhase 1

pembrolizumab (Keytruda, Pembrolizumab and Temozolomide)

Glioblastoma · Glioblastoma

#Glioblastoma#Antibody#Phase1#항체#면역항체+2
효능 ORR 54.3%임상시험 1상태 ACTIVE
AntibodystaleMerckPhase 3

pembrolizumab (Keytruda, Pembrolizumab before randomization)

Metastatic NSCLC · Metastatic NSCLC

#MetastaticNSCLC#Antibody#Phase3#항체#면역항체+2
효능 ORR 34%임상시험 1상태 RECRUITING
AntibodystaleMerckPreclinical

pembrolizumab (Keytruda, Pembrolizumab combined Anlotinib)

High-Grade Serous Ovarian Cancer · High-Grade Serous Ovarian Cancer

#High-GradeSerousOvarianCancer#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab infusion)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab or Nivolumab)

Melanoma Metastatic; BRAF V600 Mutation · Melanoma Metastatic

#MelanomaMetastatic#Antibody#Phase2#항체#면역항체+3
효능 ORR 33.3%임상시험 1상태 ACTIVE
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab plus Bevacizumab)

Melanoma; Non-small Cell Lung Cancer · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 56.3%임상시험 1상태 ACTIVE
AntibodystaleMerckPhase 2

ICE or DHAP (Pembrolizumab plus Chemotherapy, Pembrolizumab plus Chemotherapy (ICE or DHAP))

Classical Hodgkin Lymphoma · Classical Hodgkin Lymphoma

#ClassicalHodgkinLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab plus denosumab)

Renal Cell Carcinoma, Clear Cell; Metastatic Kidney Cancer · Renal Cell Carcinoma, Clear Cell

#RenalCellCarcinomaClearCell#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 ACTIVE
AntibodystaleMerckPhase 3

pembrolizumab (Keytruda, Pembrolizumab with Optional Crossover Period)

Metastatic Melanoma; Unresectable Melanoma · Metastatic Melanoma

#MetastaticMelanoma#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab+Carboplatin+albumin-bound paclitaxel:2 courses)

HNSCC; Oral Cancer · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab+Carboplatin+albumin-bound paclitaxel:4 courses)

HNSCC; Oral Cancer · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING

64 / 92 페이지

← 이전다음 →